# US 10,946,026 B2 · Pharmaceutical compositions and methods for treating mental, behavioral, cognitive disorders

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 10,946,026 B2
- Document ID: US10946026B2
- Status: Granted
- Kind: B2
- Application number: 16/424,788
- Filed: 2019-05-29
- Published: 2020-10-15
- Granted: 2021-03-16
- Earliest claimed: 2019-04-12
- Assignees: LA PharmaTech Inc.
- Applicants: LA PharmaTech Inc.
- Inventors: Jianmin Wang; Geping Cui
- Web page: https://patentgrep.com/patent/US10946026B2

## CPC

- A61K 31/55: having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K 9/0053: {Mouth and digestive tract, i.e. intraoral and peroral administration}
- A61K 31/13: Amines {(A61K31/04 takes precedence)}
- A61P 25/16: Anti-Parkinson drugs
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

A pharmaceutical composition containing the therapeutically active ingredients of azelastine or a pharmaceutically acceptable salt of azelastine and memantine or a pharmaceutically acceptable salt of memantine is disclosed. A method of using the pharmaceutical composition for treating patients suffering from mental, behavioral, cognitive disorders is also disclosed.

## Claims

### Claim 1

A method of treating a patient having Parkinson's disease, comprising:
administering a pharmaceutical composition comprising:
about 10-50 mg of azelastine or of a pharmaceutically acceptable salt of azelastine;
memantine or a pharmaceutically acceptable salt of memantine; and
one or more pharmaceutically acceptable excipients.

### Claim 2 (depends on 1)

The method of claim 1, wherein the pharmaceutical composition is administered daily to the patient in an oral solid or liquid form.

### Claim 3 (depends on 2)

The method of claim 2, wherein the azelastine or the pharmaceutically acceptable salt of azelastine is present in the pharmaceutical composition in an amount in the range of about 10 mg to about 20 mg daily.

### Claim 4 (depends on 2)

The method of claim 2, wherein the memantine or the pharmaceutically acceptable salt of memantine is present in the pharmaceutical composition in an amount in the range of about 1 mg to about 70 mg.

### Claim 5 (depends on 1)

The method of claim 1, wherein:
the azelastine or the pharmaceutically acceptable salt of azelastine is present in the pharmaceutical composition in an amount in the range of about 10 mg to about 20 mg; and
the memantine or the pharmaceutically acceptable salt of memantine is present in the pharmaceutical composition in an amount in the range of about 1 mg to about 70 mg.

### Claim 6 (depends on 1)

The method of claim 1, further comprising administering the pharmaceutical composition to the patient daily and for a period of at least twelve weeks.

### Claim 7 (depends on 1)

The method of claim 1, wherein the pharmaceutical composition comprises about 12 mg to about 20 mg of the azelastine or of the pharmaceutically acceptable salt of azelastine.

### Claim 8 (depends on 7)

The method of claim 7, wherein the memantine or the pharmaceutically acceptable salt of memantine is present in the pharmaceutical composition in an amount in the range of about 1 mg to about 70 mg.

### Claim 9 (depends on 8)

The method of claim 8, wherein the memantine or the pharmaceutically acceptable salt of memantine is present in the pharmaceutical composition in an amount in the range of about 2 mg to about 30 mg.

### Claim 10 (depends on 8)

The method of claim 8, wherein the memantine or the pharmaceutically acceptable salt of memantine is present in the pharmaceutical composition in an amount in the range of about 2 mg to about 5 mg.

### Claim 11 (depends on 8)

The method of claim 8, wherein the memantine or the pharmaceutically acceptable salt of memantine is present in the pharmaceutical composition in an amount that is equal to, greater than or less than the amount of the azelastine or of the pharmaceutically acceptable salt of azelastine.

### Claim 12 (depends on 8)

The method of claim 8, wherein the azelastine or the pharmaceutically acceptable salt of azelastine is present in the pharmaceutical composition in an amount that is 2, 3, 4, 5, 6, 7, 8, 9, or 10 times as much as the memantine or the pharmaceutically acceptable salt of memantine.

### Claim 13 (depends on 1)

The method of claim 1, wherein the memantine or the pharmaceutically acceptable salt of memantine is present in the pharmaceutical composition in an amount in the range of about 2 mg to about 30 mg.

### Claim 14 (depends on 1)

The method of claim 1, wherein the memantine or the pharmaceutically acceptable salt of memantine is present in the pharmaceutical composition in an amount in the range of about 2 mg to about 5 mg.

### Claim 15 (depends on 1)

The method of claim 1, wherein the memantine or the pharmaceutically acceptable salt of memantine is present in the pharmaceutical composition in an amount that is equal to, greater than or less than the amount of the azelastine or of the pharmaceutically acceptable salt of azelastine.

### Claim 16 (depends on 1)

The method of claim 1, wherein the azelastine or the pharmaceutically acceptable salt of azelastine is present in the pharmaceutical composition in an amount of about 12 mg and the memantine or the pharmaceutically acceptable salt of memantine is present in the pharmaceutical composition in an amount of about 5 mg.

### Claim 17 (depends on 1)

The method of claim 1, wherein the azelastine or the pharmaceutically acceptable salt of azelastine is present in the pharmaceutical composition in an amount of about 14 mg and the memantine or the pharmaceutically acceptable salt of memantine is present in the pharmaceutical composition in an amount of about 5 mg.

### Claim 18 (depends on 1)

The method of claim 1, wherein the azelastine or the pharmaceutically acceptable salt of azelastine is present in the pharmaceutical composition in an amount that is 2, 3, 4, 5, 6, 7, 8, 9, or 10 times as much as the memantine or the pharmaceutically acceptable salt of memantine.